首页> 外国专利> PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING GOSSYPOL, PHENFORMIN, AND ANTICANCER AGENT

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING GOSSYPOL, PHENFORMIN, AND ANTICANCER AGENT

机译:用于预防或治疗癌症的药物组合物,包含钆醇,苯甲酸和抗癌剂

摘要

The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agenst capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol + phenformin.
机译:本公开涉及一种包含抗癌剂组合的药物组合物,其能够在癌症治疗时产生协同效应,更具体地,本发明提出了能够在共同组合时产生协同效应的抗癌性效果用棉酚和苯甲酸施用。选择作为本公开中所述抗癌剂的抗癌剂是索拉非尼,vemurafenib,伊替替康,顺铂,紫杉醇和多柔比星,当与与古代药物和苯甲酸的三重药物组合共同施用时,每个上述抗癌剂与抑制癌症和杀伤癌细胞增殖的效果的影响,与每种单对药物治疗组和Gossypol + Phenformin的双药处理组的效果显着的协同效应。

著录项

  • 公开/公告号EP3821886A1

    专利类型

  • 公开/公告日2021-05-19

    原文格式PDF

  • 申请/专利权人 NATIONAL CANCER CENTER;

    申请/专利号EP20190834896

  • 申请日2019-05-17

  • 分类号A61K31/11;A61K31/155;A61K31/44;A61K31/437;A61K45/06;A61P35;

  • 国家 EP

  • 入库时间 2022-08-24 18:44:16

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号